HUTCHMED has finalized an exclusive license agreement with GSK granting GSK rights to develop and commercialize HMPL-A830, a novel KRAS-EGFR antibody conjugate therapy, outside China, Hong Kong, Macau, and Taiwan. This therapy targets cancers with KRAS mutations, such as colorectal, pancreatic, and lung cancers, by delivering a KRAS inhibitor directly to tumors while blocking EGFR to improve treatment efficacy and safety. HUTCHMED will lead early clinical trials, while GSK will handle later development and commercialization. HUTCHMED expects an upfront payment of $110 million and potential milestone payments up to $1.185 billion plus royalties.
GSK shares trade at USD 49.57 on Pluang as of Oct 21, 2026 07:11 WIB, up 0.22% for the day. The stock has a market cap of $99.12 billion and a dividend yield of 3.67%. Pluang investors show strong interest with 100% buy orders and a typical hold time of 94 days, reflecting steady demand for GSK amid its new licensing deal.
The FDA has approved Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. This approval is based on the AZUR-1 trial showing 68% of patients achieved complete clinical response ...
Jefferies has upgraded GSK PLC to a 'buy' rating with a 2,500p price target, suggesting a 34% gain from recent levels. This follows positive results from the EMBOLD trial of GSK's experimental lung cancer drug ris-rez, which showed a 61% tumor respon...
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
